Supernus Pharmaceuticals (SUPN) Competitors

Supernus Pharmaceuticals (NASDAQ:SUPN) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings, community ranking and media sentiment.

Do analysts rate SUPN or JAZZ?

Supernus Pharmaceuticals currently has a consensus price target of $36.00, indicating a potential upside of 12.39%. Jazz Pharmaceuticals has a consensus price target of $184.00, indicating a potential upside of 69.59%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.92

Is SUPN or JAZZ more profitable?

Jazz Pharmaceuticals has a net margin of 11.60% compared to Supernus Pharmaceuticals' net margin of 9.16%. Jazz Pharmaceuticals' return on equity of 29.30% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	9.16%	7.79%	5.67%
Jazz Pharmaceuticals	11.60%	29.30%	9.72%

Does the MarketBeat Community believe in SUPN or JAZZ?

Jazz Pharmaceuticals received 662 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. Likewise, 80.86% of users gave Jazz Pharmaceuticals an outperform vote while only 73.18% of users gave Supernus Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Supernus Pharmaceuticals	Outperform Votes 483 73.18%	Underperform Votes 177 26.82%
Jazz Pharmaceuticals	Outperform Votes 1145 80.86%	Underperform Votes 271 19.14%

Which has higher earnings & valuation, SUPN or JAZZ?

Jazz Pharmaceuticals has higher revenue and earnings than Supernus Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$668.00M	2.68	$1.32M	$1.11	28.86
Jazz Pharmaceuticals	$4.06B	1.65	$414.83M	$7.50	14.47

Which has more volatility & risk, SUPN or JAZZ?

Supernus Pharmaceuticals has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500.

Does the media favor SUPN or JAZZ?

In the previous week, Jazz Pharmaceuticals had 15 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 18 mentions for Jazz Pharmaceuticals and 3 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.76 beat Jazz Pharmaceuticals' score of 0.97 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Jazz Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in SUPN or JAZZ?

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 8.8% of Supernus Pharmaceuticals shares are held by insiders. Comparatively, 4.2% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Jazz Pharmaceuticals beats Supernus Pharmaceuticals on 13 of the 18 factors compared between the two stocks.